In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Campath, Vidaza Payments Raised In OPPS Rule; Zevalin, Bexxar Unchanged

  • News

Executive Summary

Ilex' Campath (alemtuzumab) will receive enhanced reimbursement in the hospital outpatient setting under the final 2005 OPPS rule

You may also be interested in...



Pharmion Vidaza Clears FDA With Full Approval For Bone Marrow Disorder

Pharmion plans to launch Vidaza for the treatment of myelodysplastic syndromes in July, following FDA approval May 19

Genzyme Enters Oncology Market Via $1 Bil. Acquisition Of Ilex

Genzyme will pay $1 bil. for its first marketed oncology therapeutic agent through the acquisition of Ilex Oncology

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Table

View full table

Tags:
Latest Headlines

South Korea Sees Pharma Leadership Transition

FDA-EMA Advice Pilot For Complex Generics: What Does Industry Have To Say?

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

See All
UsernamePublicRestriction

Register

PS044956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By